Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astonea LabsBOM:544409 12 Dividend Yield % is 0.00% as of Jul. 30, 2026. GuruFocus rates BOM:544409 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review. Among 512 Drug Manufacturers companies, Astonea Labs ranks worse than 195312.3% on this metric.
As of today (2026-07-30), the Trailing Annual Dividend Yield of Astonea Labs is 0.00%.
The historical rank and industry rank for Astonea Labs's Dividend Yield % or its related term are showing as below:
BOM:544409's Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.965 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Astonea Labs's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Astonea Labs's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astonea Labs Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astonea Labs's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Astonea Labs's Dividend Yield % falls into.
Astonea Labs (BOM:544409) has a Dividend Yield % of 0.00% as of Jul. 30, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Astonea Labs and its competitors. According to the industry distribution chart, Astonea Labs ranks #999999 out of 512 companies in the Drug Manufacturers industry.
Is Astonea Labs' Dividend Yield % too high?
Astonea Labs' current Dividend Yield % is 0.00%. Based on the distribution chart, Astonea Labs ranks #999999 out of 512 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Astonea Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Astonea Labs' Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Astonea Labs ranks #999999 out of 512 companies for Dividend Yield %. This places Astonea Labs in the lower half of its industry. The industry median Dividend Yield % is 1.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.97, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Astonea Labs and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astonea Labs's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astonea Labs stock overvalued right now?
Astonea Labs (BOM:544409) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Astonea Labs' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Astonea Labs (BOM:544409), the current Dividend Yield % is 0.00% as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Astonea Labs Ltd is an India-based pharmaceutical and cosmetics company engaged in the manufacturing and development of healthcare and personal care products. The Company operates in the pharmaceuticals and cosmetics & personal care space, offering products that include generic medicines, OTC products, specialty therapeutics, nutraceuticals, and biosimilars, as well as skincare, haircare, anti-aging, ethical, and organic cosmetic products, supported by in-house research and development and contract manufacturing services. Its business activities are organized across key segments comprising Pharmaceuticals, Cosmetics & Personal Care, R&D & Innovation, and Contract Manufacturing (CDMO).
12GF Score
Get the complete analysis for BOM:544409
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544409 has been successfully added to your 
